R

Rezolute Bio

Develops monoclonal antibodies for rare diseases

Director, Pharmacovigilance Operations

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote

About the Job

Requirements

  • Advanced degree in a health or life sciences discipline is strongly preferred, including MD, PharmD, PhD, RN/NP, or equivalent scientific or medical training; candidates with a master's or bachelor's degree and significant relevant pharmacovigilance leadership experience may also be considered.
  • Director candidates typically have 10 or more years of pharmaceutical or biotechnology industry experience, including approximately 7 or more years in pharmacovigilance or drug safety.
  • Director candidates have demonstrated experience supporting late-stage clinical development and/or marketed products.
  • Director candidates have experience managing outsourced pharmacovigilance operations and vendors.
  • Senior Director candidates typically have 12–15 or more years of pharmaceutical or biotechnology industry experience with progressive leadership responsibility within pharmacovigilance.
  • Senior Director candidates have demonstrated leadership of pharmacovigilance through late-stage development, regulatory approval, and commercial launch.
  • Senior Director candidates have experience establishing or significantly scaling a pharmacovigilance function, ideally within a small or mid-sized biotechnology company.
  • Senior Director candidates have experience interacting with senior executives, health authorities, strategic partners, and regulatory inspectors.
  • Strong working knowledge of global pharmacovigilance regulations and regulatory reporting requirements, ICSR management and expedited reporting, signal detection and management, aggregate safety reporting, benefit-risk assessment, risk management planning and risk minimization, safety governance, safety database and pharmacovigilance technology environments, SDEAs and partner pharmacovigilance oversight, vendor governance and outsourced pharmacovigilance models, pharmacovigilance quality systems, CAPAs, audits, inspection readiness, and clinical-to-commercial pharmacovigilance transition.
  • Candidates demonstrate the ability to interpret complex clinical and post-marketing safety information and translate it into actionable benefit-risk assessments.
  • Candidates can establish processes, governance, controls, metrics, and vendor accountability.
  • Candidates can work effectively with Clinical, Regulatory, Medical Affairs, Quality, Commercial, Legal, and executive leadership.
  • Candidates can identify material patient-safety and compliance risks and implement pragmatic solutions in a resource-conscious biotechnology environment.
  • Candidates can communicate complex safety issues clearly and concisely to senior leadership and governance committees.
  • Candidates are willing to operate strategically and tactically in a growing organization.

Responsibilities

  • Develop and execute the pharmacovigilance strategy supporting late-stage clinical development, regulatory approval, product launch, and post-marketing surveillance.
  • Establish a scalable pharmacovigilance operating model appropriate for the company's anticipated commercial footprint, product portfolio, geographic expansion, and partnership structure.
  • Serve as a senior safety leader and subject matter expert across Clinical Development, Regulatory Affairs, Medical Affairs, Quality, Commercial, Legal, and other functions.
  • Provide safety input into clinical development plans, regulatory submissions, labeling strategies, launch-readiness activities, medical information processes, and lifecycle management.
  • Represent Pharmacovigilance on cross-functional governance and product development teams.
  • At the Senior Director level, provide strategic leadership to executive management regarding emerging safety issues, benefit-risk considerations, regulatory risk, and organizational pharmacovigilance capabilities.
  • Lead pharmacovigilance readiness activities required to transition from a clinical-stage to commercial-stage organization.
  • Develop and maintain a comprehensive pharmacovigilance launch-readiness plan, including commercial adverse event intake, case processing, reconciliation, vendor interfaces, escalation pathways, reporting responsibilities, and business continuity.
  • Establish processes for adverse event and product complaint intake from Medical Affairs, Medical Information, Commercial, Market Access, patient support programs, digital channels, distributors, partners, and other potential sources.
  • Partner with Quality and Commercial to ensure appropriate identification, triage, reconciliation, and escalation of safety information associated with product complaints.
  • Establish pharmacovigilance requirements and training for employees, contractors, vendors, field-based personnel, and other groups who may receive adverse event information.
  • Ensure pharmacovigilance systems, procedures, resources, vendors, and governance structures are operational and inspection-ready before product launch.
  • Establish and oversee processes for signal detection, validation, prioritization, assessment, management, and documentation.
  • Lead cross-functional safety review or Safety Management Team meetings.
  • Provide strategic oversight of aggregate safety reports and periodic benefit-risk assessments, including applicable DSURs, PBRERs/PSURs, and other periodic reports.
  • Lead or contribute to Risk Management Plans and other risk minimization activities.
  • Partner with Regulatory Affairs and Clinical Development on safety-related labeling changes, investigator communications, regulatory responses, and health authority interactions.
  • Provide strategic and operational oversight of adverse event case management across clinical and post-marketing sources.
  • Ensure appropriate collection, assessment, processing, follow-up, quality review, and submission of ICSRs within applicable regulatory timelines.
  • Oversee pharmacovigilance vendors, including safety database providers, case-processing vendors, medical review resources, literature surveillance providers, and aggregate reporting partners.
  • Establish operational metrics, quality indicators, and vendor performance measures to monitor the effectiveness of the pharmacovigilance system.
  • Develop internal capabilities versus outsourced capabilities based on company growth, volume, geographic footprint, and portfolio requirements.
  • Ensure effective reconciliation of safety information across clinical databases, medical information, quality/product complaints, partners, patient support programs, and other relevant systems.
  • Partner with Quality Assurance to establish and maintain the company's pharmacovigilance quality system.
  • Develop, implement, and maintain pharmacovigilance policies, SOPs, work instructions, and controlled processes.
  • Establish deviation, CAPA, quality-event, and compliance-monitoring processes related to pharmacovigilance.
  • Maintain continuous pharmacovigilance inspection readiness and participate in regulatory authority inspections, partner audits, vendor audits, and internal audits.
  • Ensure documentation demonstrates effective oversight of outsourced pharmacovigilance activities.
  • Support development and maintenance of applicable pharmacovigilance system documentation and regulatory requirements, including the Pharmacovigilance System Master File where required.
  • Develop and maintain Safety Data Exchange Agreements and pharmacovigilance provisions in licensing, distribution, co-development, and commercialization agreements.
  • Establish clear responsibilities for case exchange, aggregate reporting, signal management, regulatory submissions, reconciliation, and safety governance.
  • Represent the company on joint safety committees and other alliance governance forums.
  • Monitor partner compliance with contractual pharmacovigilance obligations and implement corrective actions as necessary.
  • Maintain current knowledge of applicable global pharmacovigilance regulations and guidance, including requirements of the U.S. Food and Drug Administration, European Medicines Agency, ICH, and other relevant health authorities.
  • Ensure company pharmacovigilance processes remain compliant as products transition from investigational to marketed status and expand geographically.
  • Support preparation for health authority meetings and responses to regulatory questions regarding product safety and benefit-risk.

Desired Qualifications

  • Previous experience with NDA/BLA/MAA preparation, product launch, or post-marketing pharmacovigilance.
  • Experience with commercial safety systems such as Oracle Argus Safety or equivalent validated safety database platforms.
  • Experience with a first commercial product launch.
  • Experience transitioning biotechnology products from clinical-stage to commercial-stage.
  • Experience with NDA or BLA submission and approval.
  • Experience with U.S. and European product launches.
  • Experience building or scaling an outsourced or hybrid pharmacovigilance operating model.
  • Experience establishing post-marketing signal detection processes.
  • Experience implementing or migrating a validated safety database.
  • Experience developing and maintaining a Pharmacovigilance System Master File.
  • Experience with FDA or European health authority pharmacovigilance inspections.
  • Experience in rare disease, oncology, specialty pharmaceutical, biologic, or other relevant therapeutic areas.
  • Experience with patient support programs and specialty pharmacy safety reporting.
  • Experience with commercial product complaint/adverse event reconciliation.
  • Experience with licensing, co-development, or co-commercialization partnerships.

About the Company

Rezolute Bio

Develops monoclonal antibodies for rare diseases

Rezolute Bio develops therapies for rare diseases, led by RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. RZ358 is a human monoclonal antibody that binds insulin to reduce its activity, aiming to lessen hypoglycemia, while RZ402 is an oral plasma kallikrein inhibitor for DME. The company differentiates itself by targeting rare, unmet-need conditions and pursuing late-stage candidates in both antibody and small-molecule formats. Its goal is to bring approved therapies to patients by advancing its programs through development to commercialization.

Company size
51-200
Company stage
IPO
Headquarters
Louisville, KY
Founded
2010

Recently Posted Jobs

Explore more opportunities at Rezolute Bio

See more jobs